Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain

Journal of Neurochemistry

Volumn 98, Issue 6, 2006, Pages 1810-1816

  Ren, Yong Ri ^a   Nishida, Yoichiro ^b   Yoshimi, Kenji ^a   Yasuda, Toru ^a   Jishage, Kou Ichi ^d   Uchihara, Toshiki ^c   Yokota, Takanori ^b   Mizuno, Yoshikuni ^a   Mochizuki, Hideki ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^d Chugai Research Institute for Medical Science Inc   (Japan)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Alpha tocopherol; Dopamine; Oxidative stress; Parkinson's disease; Vitamin E

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; CARRIER PROTEIN;

ALPHA TOCOPHEROL DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; BRAIN PROTECTION; BRAIN REGION; GENOTYPE; MALE; MOUSE; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATE CORTEX; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADMINISTRATION, ORAL; ANIMALS; BRAIN; CORPUS STRIATUM; DISEASE SUSCEPTIBILITY; DOPAMINE ANTAGONISTS; GENOTYPE; GLUTATHIONE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROTOXINS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE; VITAMIN E; VITAMIN E DEFICIENCY;

EID: 33748038789     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.03994.x     Document Type: Article

References (39)

1. Adams J. D., Jr, Odunze I. N. and Sevanian A. (1990) Induction by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of lipid peroxidation in vivo in vitamin E deficient mice. Biochem. Pharmacol. 39, R5-R8.
2. Burton G. W., Joyce A. and Ingold K. U. (1983) Is vitamin E the only lipid-soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membranes? Arch. Biochem. Biophys. 221, 281-290.
3. Carrier J. C., Aghdassi E., Jeejeebhoy K. and Allard J. P. (2006) Exacerbation of dextran sulfate sodium-induced colitis by dietary iron supplementation: role of NF-kappaB. Int. J. Colorectal Dis. 21, 381-387.
4. Cheeseman K. H., Emery S., Maddix S. P., Slater T. F., Burton G.W. and Ingold K. U. (1988) Studies on lipid peroxidation in normal and tumor tissues. Biochem. J. 250, 247-252.
5. Chow C. K. (1991) Vitamin E and oxidative stress. Free Radic. Biol. Med. 11, 215-232.
6. Dexter D. T.,Ward R. J.,Wells F. R., Daniel S. E., Lees A. J., Peters T. J., Jenner P. and Marsden C. D. (1992) Alpha-tocopherol levels in brain are not altered in Parkinson's disease. Ann. Neurol. 32, 591-593.
7. Dexter D. T., Brooks D. J., Harding A. E., Burn D. J., Muller D. P., Goss-Sampson M. A., Jenner P. G. and Marsden C. D. (1994a) Nigrostriatal function in vitamin E deficiency: clinical, experimental, and positron emission tomographic studies. Ann. Neurol. 35, 298-303.
8. Dexter D. T., Nanayakkara I., Goss-Sampson M. A., Muller D. P., Harding A. E., Marsden C. D. and Jenner P. (1994b) Nigral dopaminergic cell loss in vitamin E deficient rats. Neuroreport 5, 1773-1776.
9. Fahn S. (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann. Neurol. 32, 128-132.
10. Federico A., Battisti C., Formichi P. and Dotti M. T. (1995) Plasma levels of vitamin E in Parkinson's disease. J. Neural Transm. 45(Suppl.), 267-270.
11. Furuya T., Hayakawa H., Yamada M., Yoshimi K., Hisahara S., Miura M., Mizuno Y. and Mochizuki H. (2004) Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 24, 1865-1872.
12. Hirsch E., Graybiel A. M. and Agid Y. A. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348.
13. Ithayarasi A. P. and Shyamala D. C. (1998) Effect of alpha-tocopherol on mitochondrial electron in rats. Indian J. Biochem. Biophys. 35, 115-119.
14. Jackson-Lewis V. and Smeyne R. J. (2005) MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview. Neurotox. Res. 7, 193-202.
15. Jackson-Lewis V., Jakowec M., Burke R. E. and Przedborski S. (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4, 257-269.
16. Kaempf-Rotzoll D. E., Traber M. G. and Arai H. (2003) Vitamin E and transfer proteins. Curr. Opin. Lipidol. 14, 249-254.
17. Lan J. and Jiang D. H. (1997) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm. 104, 469-481.
18. Larumbe R. (1998) Oxidative stress and Parkinson's disease. An. Sist. Sanit. Navar. 21, 187-196.
19. Luhua Z., Ying T., Zhengyu Z. and Guangji W. (2004) Determination of alpha-tocopherol in the traditional Chinese medicinal preparation sea buckthorn oil capsule by non-aqueous reversed phase-HPLC. Chem. Pharm. Bull. (Tokyo) 52, 150-152.
20. Mandir A. S., Prezedborski S., Jackson-Lewis V., Wang Z. Q., Simbulan-Rosenthal C. M., Smulson M. E., Hoffman B. E., Guastella D. B., Dawson V. L. and Dawson T. M. (1999) Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl Acad. Sci. 96, 5774-5779.
21. Mansouri A., Demeilliers C., Amsellem S., Pessayre D. and Fromenty B. (2001) Acute ethanol administration oxidatively damages and depletes mitochondrial DNA in mouse liver, brain, heart and skeletal muscles: protective effect of antioxidants. J. Pharmacol. Exp. Ther. 298, 737-743.
22. Martinovits G., Melamed E., Cohen O., Rosenthal J. and Uzzan A. (1986) Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP). Neurosci. Lett. 69, 192-197.
23. Mihatsch W., Russ H., Gerlach M., Riederer P. and Przuntek H. (1991) Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: preliminary observations. J. Neural Transm. Park. Dis. Dement. Sect. 3, 73-78.
24. Molina J. A., de Bustos F., Jimenez-Jimenez F. J., Benito-Leon J., Orti-Pareja M., Gasalla T., Tallon-Barranco A., Navarro J. A., Arenas J. and Enriquez-de-Salamanca R. (1997) Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease. J. Neural Transm. 104, 1287-1293.
25. Offen D., Ziv I., Sternin H., Melamed E. and Hochman A. (1996) Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp. Neurol. 141, 32-39.
26. Pearce R. K., Owen A., Daniel S., Jenner P. and Marsden C. D. (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 104, 661-677.
27. Perry T. L., Yong V.W., Clavier R. M., Jones K., Wright J. M., Foulks J. G. and Wall R. A. (1985) Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 60, 109-114.
28. Perry T. L.,YongV.W., Hansen S., Jones K., Bergeron C., Foulks J. G. and Wright J. M. (1987) Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. J. Neurol. Sci. 81, 321-331.
29. Przedborski S. and Vila M. (2003) The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. N Y Acad. Sci. 991, 189-198.
30. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V. L. and Dawson T. M. (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl Acad. Sci. USA 93, 4565-4571.
31. Rollema H., Fries D. S., de Vries J. B., Mastebroek D. and Horn A. S. (1985) HPLC-assay with electrochemical detection for the neurotoxin MPTP, its metabolite MPP+ and MPTP-analogues in biological samples after purification over Sephadex G10. Life Sci. 37, 1633-1640.
32. Solichova D., Korecka L., Svobodova I., Musil F., Blaha V., Zdansky P. and Zadak Z. (2003) Development and validation of HPLC method for the determination of alpha-tocopherol in human erythrocytes for clinical applications. Anal. Bioanal. Chem. 376, 444-447.
33. Sriram K., Pai K. S., Boyd M. R. and Ravindranath V. (1997) Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res. 749, 44-52.
34. Tappel A. L. (1962) Vitamin E as the biological lipid antioxidant. Vitam. Horm. 20, 493-510.
35. The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl. J. Med. 328, 176-183.
36. Traber M. G. and Sies H. (1996) Vitamin E in humans: demand and delivery. Annu. Rev. Nutr. 16, 321-347.
37. Yokota T., Igarashi K., Uchihara T. et al. (2001) Delayed-onset ataxia in mice lacking alpha-tocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress. Proc. Natl Acad. Sci. USA 98, 15 185-15 190.
38. Yong V. W., Perry T. L. and Krisman A. A. (1986) Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. Neurosci. Lett. 63, 56-60.
39. Yoshikawa T. (1993) Free radicals and their scavengers in Parkinson's disease. Eur. Neurol. 33, 60-68.